FGF23 induces left ventricular hypertrophy

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369

Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology

Lang, R. M., Bierig, M., Devereux, R. B., Flachskampf, F. A., Foster, E., Pellikka, P. A., Picard, M. H., Roman, M. J., Seward, J., Shanewise, J. S., et al. (2005) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2005.10.005 · Cited by 11,318

Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart study

Levy, D., Garrison, R. J., Savage, D. D., Kannel, W. B., & Castelli, W. P. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005313222203 · Cited by 5,699

Prevalence of Chronic Kidney Disease in the United States

Coresh, J., Selvin, E., Stevens, L. A., Manzi, J., Kusek, J. W., Eggers, P., Van Lente, F., & Levey, A. S. (2007) · JAMA · doi:10.1001/jama.298.17.2038 · Cited by 4,895

Mutation of the mouse klotho gene leads to a syndrome resembling ageing

Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837

A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy

Molkentin, J. D., Lu, J., Antos, C. L., Markham, B. E., Richardson, J. A., Robbins, J. M., Grant, S. R., & Olson, E. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81573-1 · Cited by 2,566

Fibroblast growth factors.

Ornitz, D. M., & Itoh, N. (2001) · Genome biology · doi:10.1186/gb-2001-2-3-reviews3005 · Cited by 1,985

Cellular signaling by fibroblast growth factor receptors

Eswarakumar, V. P., Lax, I., & Schlessinger, J. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.001 · Cited by 1,923

Regulation of cardiac hypertrophy by intracellular signalling pathways

Heineke, J., & Molkentin, J. D. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1983 · Cited by 1,890

Receptor Specificity of the Fibroblast Growth Factor Family

Ornitz, D. M., Xu, J., Colvin, J. S., McEwen, D. G., MacArthur, C. A., Coulier, F., Gao, G., & Goldfarb, M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.25.15292 · Cited by 1,871

Circadian rhythm of activin A and related parameters of mineral metabolism in normal and uremic rats

Nordholm, A., Egstrand, S., Gravesen, E., Mace, M. L., Morevati, M., Ølgaard, K., & Lewin, E. (2019) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-019-02291-2 · Cited by 30

Slc20a1/Pit1 and Slc20a2/Pit2 are essential for normal skeletal myofiber function and survival

Chande, S., Caballero, D., Ho, B., Fetene, J. A., Serna, J., Pesta, D. H., Nasiri, A. R., Jurczak, M. J., Chavkin, N. W., Hernando, N., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-59430-4 · Cited by 34

Fluctuating plasma phosphorus level by changes in dietary phosphorus intake induces endothelial dysfunction

Watari, E., Taketani, Y., Kitamura, T., Tanaka, T., Ohminami, H., Abuduli, M., Harada, N., Yamanaka‐Okumura, H., Yamamoto, H., & Takeda, E. (2014) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.14-96 · Cited by 29

Hepatic Production of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease

Bienaimé, F., Ambolet-Camoit, A., Aussilhou, B., Brazier, F., Fouchard, M., Viau, A., Barre, P., Tissier, A.-M., Corréas, J.-M., Paradis, V., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00123 · Cited by 29

Phosphate and Cardiovascular Disease beyond Chronic Kidney Disease and Vascular Calcification

Disthabanchong, S. (2018) · International Journal of Nephrology · doi:10.1155/2018/3162806 · Cited by 30

Non-renal-Related Mechanisms of FGF23 Pathophysiology

Hanudel, M. R., Laster, M. L., & Salusky, I. B. (2018) · Current Osteoporosis Reports · doi:10.1007/s11914-018-0492-2 · Cited by 30

The Incidence and Associated Factors of Sudden Death in Patients on Hemodialysis: 10-Year Outcome of the Q-Cohort Study

Hiyamuta, H., Tanaka, S., Taniguchi, M., Tokumoto, M., Fujisaki, K., Nakano, T., Tsuruya, K., & Kitazono, T. (2019) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.49833 · Cited by 28

Current Understanding of Mineral and Bone Disorders of Chronic Kidney Disease and the Scientific Grounds on the Use of Exogenous Parathyroid Hormone in Its Management

Pazianas, M., & Miller, P. D. (2020) · Journal of Bone Metabolism · doi:10.11005/jbm.2020.27.1.1 · Cited by 29

Cardiovascular Disease Risk Factors in Chronic Kidney Disease in Children

Mitsnefes, M. M. (2021) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2021.09.005 · Cited by 29

The influence of vitamin D analogs on calcification modulators, N-terminal pro-B-type natriuretic peptide and inflammatory markers in hemodialysis patients: a randomized crossover study

Hansen, D., Rasmussen, K., Rasmussen, L. M., Brüünsgaard, H., & Brandi, L. (2014) · BMC Nephrology · doi:10.1186/1471-2369-15-130 · Cited by 29

High dose intravenous iron, mineral homeostasis and intact FGF23 in normal and uremic rats

Gravesen, E., Hofman-Bang, J., Mace, M. L., Lewin, E., & Ølgaard, K. (2013) · BMC Nephrology · doi:10.1186/1471-2369-14-281 · Cited by 29

DNMT1 and HDAC2 Cooperate to Facilitate Aberrant Promoter Methylation in Inorganic Phosphate-Induced Endothelial-Mesenchymal Transition

Tan, X., Xu, X., Zeisberg, M., & Zeisberg, E. M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147816 · Cited by 29

Central blood pressure and chronic kidney disease

Ohno, Y. (2016) · World Journal of Nephrology · doi:10.5527/wjn.v5.i1.90 · Cited by 29

Autosomal dominant polycystic kidney disease and the heart and brain

Krishnappa, V., Vinod, P., Deverakonda, D. L., & Raina, R. (2017) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.84a.16107 · Cited by 29

Vitamin D and Kidney Disease. What we know and what we do not know

Filho, A. J. I., & Melamed, M. L. (2013) · Brazilian Journal of Nephrology · doi:10.5935/0101-2800.20130051 · Cited by 28

FGF23 and Nutritional Metabolism

Pool, L. R., & Wolf, M. S. (2017) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071816-064620 · Cited by 29

Cardioprotective Effects of Paricalcitol Alone and in Combination With FGF23 Receptor Inhibition in Chronic Renal Failure: Experimental and Clinical Studies

Czaya, B. A., Seeherunvong, W., Singh, S., Yanucil, C., Ruiz, P., Quiroz, Y., Grabner, A., Katsoufis, C. P., Swaminathan, S., Abitbol, C. L., et al. (2018) · American Journal of Hypertension · doi:10.1093/ajh/hpy154 · Cited by 29

Phosphate and fibroblast growth factor 23 in diabetes

van der Vaart, A., Yeung, S. M. H., van Dijk, P. R., Bakker, S. J. L., & de Borst, M. H. (2021) · Clinical Science · doi:10.1042/cs20201290 · Cited by 28

Biomarkers associated with rhythm status after cardioversion in patients with atrial fibrillation

Meyre, P. B., Aeschbacher, S., Blum, S., Voellmin, G., Kastner, P., Hennings, E., Kaufmann, B. A., Kühne, M., Osswald, S., & Conen, D. (2022) · Scientific Reports · doi:10.1038/s41598-022-05769-9 · Cited by 27

Serum Phosphate and Long-Term Outcome Among Patients With Stable Heart Failure

Ess, M., Heitmair-Wietzorrek, K., Frick, M., Umlauf, N., Ulmer, H., & Poelzl, G. (2012) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2012.11.008 · Cited by 28

Association of serum levels of FGF23 and α-Klotho with glomerular filtration rate and proteinuria among cardiac patients

Ozeki, M., Fujita, S.-I., Kizawa, S., Morita, H., Sohmiya, K., Hoshiga, M., & Ishizaka, N. (2014) · BMC Nephrology · doi:10.1186/1471-2369-15-147 · Cited by 28

Vitamin D action

Tiosano, D., & Gepstein, V. (2012) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32835a3415 · Cited by 31

Fibroblast Growth Factor 23 and Incident CKD in Type 2 Diabetes

Isakova, T., Craven, T. E., Lee, J. J., Scialla, J. J., Xie, H., WAHL, P. W., Marcovina, S. M., Byington, R. P., & Wolf, M. S. (2014) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06190614 · Cited by 28

Management of hyperphosphataemia in chronic kidney disease--challenges and solutions

Ketteler, M., Wuthrich, R. P., & Floege, J. (2013) · Clinical Kidney Journal · doi:10.1093/ckj/sfs173 · Cited by 28

Oncostatin M Induces FGF23 Expression in Cardiomyocytes

Richter, M., Polyakova, V. O., & Gajawada, P. (2012) · Journal of Clinical & Experimental Cardiology · doi:10.4172/2155-9880.s9-003 · Cited by 28

Prognostic value of bone- and vascular-derived molecular biomarkers in hemodialysis and renal transplant patients: a systematic review and meta-analysis

Pichler, G., Haller, M. C., Kainz, A., Wolf, M. S., Redón, J., & Oberbauer, R. W. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw387 · Cited by 28

High fibroblast growth factor 23 levels are associated with decreased ferritin levels and increased intravenous iron doses in hemodialysis patients

Honda, H., Michihata, T., Shishido, K., Takahashi, K., Takahashi, G., Hosaka, N., Ikeda, M., Sanada, D., & Shibata, T. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176984 · Cited by 28

The direct effect of fibroblast growth factor 23 on vascular smooth muscle cell phenotype and function

Vergara, N., de Mier, M. V. P.-R., Rodelo‐Haad, C., Revilla-González, G., Membrives, C., Díaz‐Tocados, J. M., Martinez-Moreno, J. M., Torralbo, A. I., Herencia, C., Rodríguez-Ortiz, M. E., et al. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac220 · Cited by 27

Roles of PTH and FGF23 in kidney failure: a focus on nonclassical effects

Komaba, H. (2023) · Clinical and Experimental Nephrology · doi:10.1007/s10157-023-02336-y · Cited by 27

The Dietary Fiber Inulin Slows Progression of Chronic Kidney Disease–Mineral Bone Disorder (CKD‐MBD) in a Rat Model of CKD

Biruete, A., Chen, N. X., Metzger, C. E., Srinivasan, S., O’Neill, K. D., Fallen, P. B., Fonseca, A., Wilson, H. E., de Loor, H., Evenepoel, P., et al. (2023) · JBMR Plus · doi:10.1002/jbm4.10837 · Cited by 27

Novel Perspectives in Chronic Kidney Disease-Specific Cardiovascular Disease

Xu, C., Tsihlis, G., Chau, K., Trinh, K., Rogers, N. M., & Julovi, S. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052658 · Cited by 30

Emerging drugs for secondary hyperparathyroidism

Cozzolino, M. G., Tomlinson, J., Walsh, L., & Bellasi, A. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1018177 · Cited by 27

Competitive Interaction Between Fibroblast Growth Factor 23 And Asymmetric Dimethylarginine in Patients With CKD

Tripepi, G. L., Kollerits, B., Leonardis, D., Yilmaz, M. I., Postorino, M., Fliser, D., Mallamaci, F., Kronenberg, F., & Zoccali, C. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013121355 · Cited by 27

Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis

Parfrey, P. S., Block, G. A., Correa‐Rotter, R., Drüeke, T. B., Floege, J., Herzog, C. A., London, G. M., Mahaffey, K. W., Moe, S. M., Wheeler, D. C., et al. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06370615 · Cited by 27

FGF23 regulation of renal tubular solute transport

Erben, R. G., & Andrukhova, O. (2015) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000145 · Cited by 27

FGF23 effects on the heart—levels, time, source, and context matter

Faul, C. (2018) · Kidney International · doi:10.1016/j.kint.2018.03.024 · Cited by 27

The cardiovascular–dialysis nexus: the transition to dialysis is a treacherous time for the heart

Chan, K. T. K., Moe, S. M., Saran, R., & Libby, P. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1049 · Cited by 32

Treatment of secondary hyperparathyroidism in non-dialysis CKD: an appraisal 2022s

Ketteler, M., Bover, J., & Mazzaferro, S. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac236 · Cited by 27

Fibroblast growth factor-23 and the risk of cardiovascular diseases and mortality in the general population: A systematic review and dose-response meta-analysis

Liu, M., Xia, P., Tan, Z., Song, T., Mei, K., Wang, J., Ma, J., Jiang, Y., Zhang, J., Zhao, Y., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.989574 · Cited by 27

Zebrafish as a Model of Cardiac Pathology and Toxicity: Spotlight on Uremic Toxins

Coppola, A., Lombari, P., Mazzella, E., Capolongo, G., Simeoni, M., Perna, A. F., Ingrosso, D., & Borriello, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065656 · Cited by 32

Osteocytic Protein Expression Response to Doxercalciferol Therapy in Pediatric Dialysis Patients

Pereira, R. C., Jüppner, H., Gales, B., Salusky, I. B., & Wesseling‐Perry, K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120856 · Cited by 27

Fibroblast growth factor 23 is upregulated in the kidney in a chronic kidney disease rat model

Sugiura, H., Matsushita, A., Futaya, M., Teraoka, A., Akiyama, K., Usui, N., Nagano, N., Nitta, K., & Tsuchiya, K. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191706 · Cited by 27

Elevated FGF23 Levels in Mice Lacking the Thiazide-Sensitive NaCl cotransporter (NCC)

Pathare, G., Anderegg, M. A., Albano, G. D., Lang, F. J. W., & Fuster, D. G. (2018) · Scientific Reports · doi:10.1038/s41598-018-22041-1 · Cited by 27

Fibroblast Growth Factor 23 and Adverse Clinical Outcomes in Type 2 Diabetes: a Bitter-Sweet Symphony

Yeung, S. M. H., Bakker, S. J. L., Laverman, G. D., & de Borst, M. H. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01335-7 · Cited by 27

Biomarkers of iron metabolism in chronic kidney disease

Głogowski, T., Wojtaszek, E., & Małyszko, J. (2020) · International Urology and Nephrology · doi:10.1007/s11255-020-02663-z · Cited by 33

Vitamin D: a dynamic molecule. How relevant might the dynamism for a vitamin be?

Mazzaferro, S., & Pasquali, M. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv340 · Cited by 26

Wound healing delays in α-Klotho-deficient mice that have skin appearance similar to that in aged humans – Study of delayed wound healing mechanism

Yamauchi, M., Hirohashi, Y., Torigoe, T., Matsumoto, Y., Yamashita, K., Kayama, M., Sato, N., & Yotsuyanagi, T. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.03.138 · Cited by 27

Cinacalcet for Treatment of Chronic Kidney Disease-Mineral and Bone Disorder: A Meta-Analysis of Randomized Controlled Trials

Greeviroj, P., Kitrungphaiboon, T., Katavetin, P., Praditpornsilpa, K., Eiam‐Ong, S., Jaber, B. L., & Susantitaphong, P. (2018) · The Nephron journals/Nephron journals · doi:10.1159/000487546 · Cited by 26

Role of Klotho in bone and implication for CKD

Komaba, H., & Lanske, B. (2018) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000423 · Cited by 26

Waist-to-height ratio, body mass index, and cardiovascular risk profile in children with chronic kidney disease

Sgambat, K., Roem, J., Mitsnefes, M. M., Portale, A. A., Furth, S. L., Warady, B. A., & Moudgil, A. (2018) · Pediatric Nephrology · doi:10.1007/s00467-018-3987-2 · Cited by 26

Vitamin D and kidney disease

Keung, L., & Perwad, F. (2018) · Bone Reports · doi:10.1016/j.bonr.2018.07.002 · Cited by 26

Effects of Potassium or Sodium Supplementation on Mineral Homeostasis: A Controlled Dietary Intervention Study

Humalda, J. K., Yeung, S. M. H., Geleijnse, J. M., Gijsbers, L., Riphagen, I. J., Hoorn, E. J., Rotmans, J. I., Vogt, L., Navis, G., Bakker, S. J. L., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa359 · Cited by 26

Alpha-Klotho is a novel predictor of treatment responsiveness in patients with heart failure

Taneike, M., Nishida, M., Nakanishi, K., Sera, F., Kioka, H., Yamamoto, R., Ohtani, T., Hikoso, S., Moriyama, T., Sakata, Y., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-81517-9 · Cited by 26

Tyrosine and Tryptophan vibrational bands as markers of kidney injury: a renocardiac syndrome induced by renal ischemia and reperfusion study

Nepomuceno, G. L. J. T., Junho, C. V. C., Carneiro‐Ramos, M. S., & Martinho, H. D. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-93762-z · Cited by 26

Serum phosphate and chronic kidney and cardiovascular disease: Phosphorus potential implications in general population

Raikou, V. D. (2021) · World Journal of Nephrology · doi:10.5527/wjn.v10.i5.76 · Cited by 28

Interrelation between heart failure with preserved ejection fraction and renal impairment

Joslin, J. R., Lioudaki, E., & Androulakis, E. S. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2302069 · Cited by 27

Frontier and Hotspot Evolution in Cardiorenal Syndrome: A Bibliometric Analysis From 2003 to 2022

Lv, J., Li, Y., Shi, S., Liu, S., Xu, X., Wu, H., Zhang, B., & Song, Q. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101238 · Cited by 26

Fibroblast Growth Factor 23 and Risk of New Onset Heart Failure With Preserved or Reduced Ejection Fraction: The PREVEND Study

Binnenmars, S. H., Hoogslag, G. E., Yeung, S. M. H., Brouwers, F. P. J., Bakker, S. J. L., van Gilst, W. H., Gansevoort, R. T., Navis, G. J., Voors, A. A., & de Borst, M. H. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.024952 · Cited by 26

Physiopathology of Phosphate Disorders

Portales-Castillo, I., Rieg, T., Khalid, S. B., Nigwekar, S. U., & Neyra, J. A. (2023) · Advances in Kidney Disease and Health · doi:10.1053/j.akdh.2022.12.011 · Cited by 26

Estimated GFR and Subsequent Higher Left Ventricular Mass in Young and Middle-Aged Adults With Normal Kidney Function: The Coronary Artery Risk Development in Young Adults (CARDIA) Study

Bansal, N., Lin, F., Vittinghoff, E., Peralta, C. A., Lima, J. A. C., Kramer, H., Shlipak, M. G., & Bibbins-Domingo, K. B. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.06.024 · Cited by 26

Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease–mineral bone disorders (CKD-MBD) in children

Wesseling‐Perry, K., & Salusky, I. B. (2013) · Pediatric Nephrology · doi:10.1007/s00467-012-2381-8 · Cited by 26

A Systems Biology Preview of the Relationships Between Mineral and Metabolic Complications in Chronic Kidney Disease

Quarles, L. D. (2013) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2012.12.014 · Cited by 25

Elevated Cardiac Markers in Chronic Kidney Disease as a Consequence of Hyperphosphatemia-Induced Cardiac Myocyte Injury

Peng, A. (2014) · Medical Science Monitor · doi:10.12659/msm.890909 · Cited by 26

Resurgence of parathyroidectomy

Komaba, H., Nakamura, M., & Fukagawa, M. (2017) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000326 · Cited by 26

Association of Tenofovir Use With Risk of Incident Heart Failure in HIV‐Infected Patients

Chen, R., Scherzer, R., Hsue, P. Y., Jotwani, V., Estrella, M. M., Horberg, M. A., Grünfeld, C., & Shlipak, M. G. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005387 · Cited by 26

The Rationale for Expanded Hemodialysis Therapy (HDx)

Hutchison, C. A., & Wolley, M. J. (2017) · Contributions to nephrology · doi:10.1159/000479262 · Cited by 26

Outcome Prediction of Acute Kidney Injury Biomarkers at Initiation of Dialysis in Critical Units

Wu, V., Shiao, C., Chi, N., Wang, C., Chueh, S., Liou, H., Spapen, H. D., Honoré, P. M., & Chu, T. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7080202 · Cited by 26

The Association of Fibroblast Growth Factor 23 with Arterial Stiffness and Atherosclerosis in Patients with Autosomal Dominant Polycystic Kidney Disease

Çoban, M., İnci, A., Yılmaz, Ü., & Asiltürk, E. (2018) · Kidney & Blood Pressure Research · doi:10.1159/000492244 · Cited by 26

Serum NGAL and FGF23 may have certain value in early diagnosis of CIN

Li, H., Yu, Z., Gan, L., Peng, L., & Zhou, Q. (2018) · Renal Failure · doi:10.1080/0886022x.2018.1487860 · Cited by 26

Pathophysiological Mechanisms in Cardiorenal Syndrome

Rangaswami, J., & Mathew, R. O. (2018) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2018.08.006 · Cited by 26

Active Vitamin D in Chronic Kidney Disease: Getting Right Back Where We Started from?

Negrea, L. A. (2018) · Kidney Diseases · doi:10.1159/000495138 · Cited by 26

Treatment of hyperphosphatemia: the dangers of high PTH levels

Bacchetta, J. (2019) · Pediatric Nephrology · doi:10.1007/s00467-019-04400-w · Cited by 26

Short daily hemodialysis is associated with lower plasma FGF23 levels when compared with conventional hemodialysis

Zaritsky, J. J., Rastogi, A., Fischmann, G. P. A., Yan, J. Y., KLEINMAN, K. P., Chow, G., Gales, B., Salusky, I. B., & Wesseling‐Perry, K. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft382 · Cited by 26

FGF-23/Vitamin D Axis in Type 1 Diabetes: The Potential Role of Mineral Metabolism in Arterial Stiffness

Llauradó, G., Megía, A., Cano, A., Giménez‐Palop, O., Simón, I., González-Sastre, M., Berlanga, E., Fernández‐Veledo, S., Vendrell, J. J., & González-Clemente, J. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140222 · Cited by 25

Serum phosphorus is related to left ventricular remodeling independent of renal function in hospitalized patients with chronic kidney disease

Zou, J., Yu, Y., Wu, P., Lin, F. F., Yao, Y., Xie, Y., & Jiang, G.-R. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.181 · Cited by 25

Type 4 cardiorenal syndrome

da Silva, A. L. P., & Vaz‐da‐Silva, M. (2016) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2016.06.007 · Cited by 25

Circulating FGF23 is not associated with cardiac dysfunction, atherosclerosis, infection or inflammation in hemodialysis patients

Takashi, Y., Wakino, S., Minakuchi, H., Ishizu, M., Kuroda, A., Shima, H., Tashiro, M., Miya, K., Okada, K., Minakuchi, J., et al. (2019) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-019-01027-7 · Cited by 25

Inflammation both increases and causes resistance to FGF23 in normal and uremic rats

Rodríguez-Ortiz, M. E., Díaz‐Tocados, J. M., Muñoz-Castañeda, J. R., Herencia, C., Pineda, C., Martinez-Moreno, J. M., de Oca, A. M., López‐Baltanás, R., Alcala-Diaz, J. F., Ortíz, A., et al. (2020) · Clinical Science · doi:10.1042/cs20190779 · Cited by 25

Complications of Phosphate and Vitamin D Treatment in X-Linked Hypophosphataemia

Sancho, P. A. (2020) · Advances in Therapy · doi:10.1007/s12325-019-01170-7 · Cited by 25

Inflammation, Oxidative Stress, and Bone in Chronic Kidney Disease in the Osteoimmunology Era

Mazzaferro, S., Bagordo, D., Martini, N. D., Pasquali, M., Rotondi, S., Tartaglione, L., Stenvinkel, P., & the ERA-EDTA CKD-MBD working group (2021) · Calcified Tissue International · doi:10.1007/s00223-020-00794-0 · Cited by 25

Indoxyl sulfate in uremia: an old idea with updated concepts

Berg, A. H., Kumar, S., & Karumanchi, S. A. (2022) · Journal of Clinical Investigation · doi:10.1172/jci155860 · Cited by 25

FGF21-FGFR4 signaling in cardiac myocytes promotes concentric cardiac hypertrophy in mouse models of diabetes

Yanucil, C., Kentrup, D., Li, X., Grabner, A., Schramm, K. J., Martinez, E. C., Li, J., Campos, I. D., Czaya, B. A., Heitman, K., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-11033-x · Cited by 25

Research Highlight: Chronic sustained inflammation links to left ventricular hypertrophy and aortic valve sclerosis: a new link between S100/RAGE and FGF23

Yan, L., & Bowman, M. A. H. (2014) · Inflammation and Cell Signaling · doi:10.14800/ics.279 · Cited by 25

Phosphate: an old bone molecule but new cardiovascular risk factor

Shobeiri, N., Adams, M. A., & Holden, R. M. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12117 · Cited by 27

Fibroblast growth factor 23, the ankle-brachial index, and incident peripheral artery disease in the Cardiovascular Health Study

Garimella, P. S., Ix, J. H., Katz, R., Chonchol, M. B., Kestenbaum, B. R., de Boer, I. H., Siscovick, D. S., Shastri, S., Hiramoto, J. S., Shlipak, M. G., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.12.015 · Cited by 25

Pathophysiological Implications of Fibroblast Growth Factor-23 and Klotho and Their Potential Role as Clinical Biomarkers

Donate‐Correa, J., de Fuentes, M. M., Fernández, C. M., & Navarro‐González, J. F. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2013.206649 · Cited by 25

Effects of klotho deletion from bone during chronic kidney disease

Kaludjerovic, J., Komaba, H., & Lanske, B. (2017) · Bone · doi:10.1016/j.bone.2017.02.006 · Cited by 25

Effects of lower versus higher phosphate diets on fibroblast growth factor-23 levels in patients with chronic kidney disease: a systematic review and meta-analysis

Tsai, W., Wu, H., Peng, Y., Hsu, S., Chiu, Y., Chen, H., Yang, J., Ko, M., Pai, M., Tu, Y., et al. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy005 · Cited by 25

Iron deficiency after kidney transplantation

Vinke, J. S. J., Francke, M. I., Eisenga, M. F., Hesselink, D. A., & de Borst, M. H. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa123 · Cited by 28

Fibroblast growth factor-23 is associated with imaging markers of diabetic cardiomyopathy and anti-diabetic therapeutics

Sørensen, M. H., Bojer, A. S., Jørgensen, N. R., Broadbent, D. A., Plein, S., Madsen, P. L., & Gæde, P. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01135-z · Cited by 26

Development of Cancer in Patients With Heart Failure: How Systemic Inflammation Can Lay the Groundwork

Ausoni, S., & Azzarello, G. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.598384 · Cited by 23

Fibroblast growth factor 23 (FGF23) induces ventricular arrhythmias and prolongs QTc interval in mice in an FGF receptor 4-dependent manner

Graves, J. M., Vallejo, J. A., Hamill, C. S., Wang, D. D., Ahuja, R., Patel, S., Faul, C., & Wacker, M. (2021) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00798.2020 · Cited by 27

Hyperphosphatemia in Kidney Failure: Pathophysiology, Challenges, and Critical Role of Phosphorus Management

Saxena, R., & Raju, S. (2025) · Nutrients · doi:10.3390/nu17091587 · Cited by 27

Association between circulating FGF23, α-Klotho, and left ventricular diastolic dysfunction among patients with preserved ejection fraction

Okamoto, Y., Fujita, S.-I., Morita, H., Kizawa, S., Ito, T., Sakane, K., Sohmiya, K., Hoshiga, M., & Ishizaka, N. (2014) · Heart and Vessels · doi:10.1007/s00380-014-0581-9 · Cited by 24

COVID-19 in Chronic Kidney Disease: The Impact of Old and Novel Cardiovascular Risk Factors

Podestà, M. A., Valli, F., Galassi, A., Cassia, M. A., Ciceri, P., Barbieri, L., Carugo, S., & Cozzolino, M. G. (2021) · Blood Purification · doi:10.1159/000514467 · Cited by 27

Cardiac Fibroblast Growth Factor 23 Excess Does Not Induce Left Ventricular Hypertrophy in Healthy Mice

Leifheit‐Nestler, M., Wagner, M., Richter, B., Piepert, C., Eitner, F., Böckmann, I., Vogt, I., Grund, A., Hille, S. S., Foinquinos, A., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.745892 · Cited by 24

Klotho and Mesenchymal Stem Cells: A Review on Cell and Gene Therapy for Chronic Kidney Disease and Acute Kidney Disease

Franco, M. L., Beyerstedt, S., & Rangel, É. B. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics14010011 · Cited by 27

Echocardiographic manifestations in end-stage renal disease

Ito, T., & Akamatsu, K. (2023) · Heart Failure Reviews · doi:10.1007/s10741-023-10376-5 · Cited by 25

Fibroblast Growth Factor 23 and Sudden Versus Non-sudden Cardiac Death: The Cardiovascular Health Study

Deo, R., Katz, R., de Boer, I. H., Sotoodehnia, N., Kestenbaum, B. R., Mukamal, K. J., Chonchol, M., Sarnak, M. J., Siscovick, D. S., Shlipak, M. G., et al. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.10.025 · Cited by 24

Impact of hemodialysis, left ventricular mass and FGF-23 on myocardial mechanics in end-stage renal disease: a three-dimensional speckle tracking study

Kovács, A. D., Tapolyai, M. B., Celeng, C., Gara, E., Faludi, M., Berta, K., Apor, A., Nagy, A., Tislér, A., & Merkely, B. P. (2014) · International journal of cardiac imaging · doi:10.1007/s10554-014-0480-2 · Cited by 25

Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease

Leifheit‐Nestler, M., Siemer, R. G., Flasbart, K., Richter, B., Kirchhoff, F., Ziegler, W. H., Klintschar, M., Becker, J. U., Erbersdobler, A., Aufricht, C., et al. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv421 · Cited by 207

Connecting the dots on fibroblast growth factor 23 and left ventricular hypertrophy

Gutiérrez, O. M. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv445 · Cited by 5

SaO027CARDIO-PATHOLOGICAL EFFECTS OF FGF23 IN CKD ARE MEDIATED BY FGFR4

Grabner, A., Amaral, A. P., Singh, S., Schramm, K. J., Sloan, A. J., Kentrup, D., Reuter, S., Pavenstaedt, H., Marco, G. S. D., Wolf, M., et al. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv150.04

FGF-23, Left Ventricular Hypertrophy, and Mortality in Patients With CKD

Hidaka, N., Inoue, K., Katô, H., Hoshino, Y., Koga, M., Kinoshita, Y., Takashi, Y., Makita, N., Fukumoto, S., Nangaku, M., et al. (2023) · JACC Advances · doi:10.1016/j.jacadv.2023.100747 · Cited by 13

Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease

Gutiérrez, O. M., Januzzi, J. L., Isakova, T., Laliberte, K. A., Smith, K., Collerone, G., Sarwar, A., Hoffmann, U., Coglianese, E. E., Christenson, R. H., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.844506 · Cited by 843